Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biologics
Biotech
Ocugen update charts course for rivalry with Apellis, Astellas
Ocugen reported phase 2 data on its eye disease gene therapy, providing evidence that the candidate may outperform drugs from Apellis and Astellas.
Nick Paul Taylor
Jan 15, 2026 9:22am
Takeda leader says AI gave early-stage asset a 'phoenix' rebirth
Jan 13, 2026 6:16am
Fierce Pharma
Orca rides $250M funding wave toward cancer cell therapy launch
Jan 9, 2026 11:19am
Flagship-founded Tessera plans to lay off 90 employees in March
Jan 8, 2026 10:00am
UK biotech eyes $1B deal to deliver eye gene therapy at doctor
Jan 6, 2026 6:25am
Fierce Biotech's 10 most-read stories of 2025
Dec 29, 2025 7:00am
